73 Series B biotech investors
We list 73 Series B biotech investors as of November 2026: 34 have an SEC filing on file and 39 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (11), New York (7) and Massachusetts (3).
Top 5 Series B biotech investors, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Claret Capital Partners
Type: Venture debt · HQ: London, United Kingdom · Stages: Series B, Growth, Late stage · Focus: Biotech, Healthtech, Climate Tech, SaaS · Latest activity: New deal, Oct 2026 · Fund size or assets: €575M (own site)
Dated new deal in Oct 2026; €575M on file (own site); states biotech and life sciences as a focus; backs Series B, growth-stage, late stage; 8 named decision-makers on file.
HBM Partners
Type: Fund manager · HQ: Zug, Switzerland · Stages: Series A, Series B, Growth, Late stage · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: $2.8B (own site)
Portfolio news dated Oct 2026; $2.8B on file (own site); states biotech and life sciences as a focus; backs Series A, Series B, growth-stage; 1 named decision-maker on file.
Andera Partners
Type: Fund manager · HQ: Paris, France · Stages: Seed, Series A, Series B, Growth · Focus: Biotech, Medtech, Healthtech, Generalist · Latest activity: Portfolio news, Sep 2026 · Fund size or assets: €6.0B (own site)
Portfolio news dated Sep 2026; €6.0B on file (own site); states biotech and life sciences as a focus; backs seed, Series A, Series B.
BGF
Type: VC firm · HQ: United Kingdom · Stages: Seed, Series A, Series B, Growth · Focus: Biotech, Healthtech, Edtech, Developer Tools · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: £3.0B (own site)
Portfolio news dated Oct 2026; £3.0B on file (own site); 20% of its observed portfolio is biotech and life sciences; backs seed, Series A, Series B; 8 named decision-makers on file.
Hadean Ventures
Type: VC firm · HQ: Norway · Stages: Seed, Series A, Series B · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Sep 2026 · Fund size or assets: €230M (own site)
Dated new deal in Sep 2026; €230M on file (own site); states biotech and life sciences as a focus; backs seed, Series A, Series B; 3 named decision-makers on file.
First 25 of 73 Series B biotech investors
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Biotech, Healthtech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 4 Nov 2026 | 8 names · Unlock |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 4 Nov 2026 | 8 names · Unlock |
| Hadean Ventures | VC firm | Norway | Seed, Series A, Series B | Biotech, Healthtech, Medtech | New deal, Sep 2026 | €230M (own site) | 7 Nov 2026 | 3 names, firm email · Unlock |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 4 Nov 2026 | 2 names, firm email · Unlock |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 5 Nov 2026 | 8 names · Unlock |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 4 Nov 2026 | 1 name · Unlock |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 4 Nov 2026 | 8 names · Unlock |
| Calculus VC | VC firm | Foster City, CA | Series A, Series B | Biotech, AI, Deep Tech, Healthtech | New deal, Aug 2026 | $1M (SEC Form D, 2025) | 4 Nov 2026 | 1 name, firm email · Unlock |
| How Women Invest | VC firm | Oakland, CA | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, B2B | New fund, Sep 2026 | $12M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
| Arboretum Ventures | VC firm | Ann Arbor, MI | Series A, Series B | Biotech, Healthtech, Medtech | Portfolio news, Mar 2026 | $250M (SEC Form D, 2022) | 5 Nov 2026 | 7 names · Unlock |
| Cultivation Capital | VC firm | St. Louis, MO | Seed, Series A, Series B | Biotech, Healthtech, SaaS, Agritech | New fund, Sep 2026 | $100M (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| Apple Tree Venture | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | Portfolio news, Sep 2025 | $3.5B (SEC Form ADV) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Industrifonden | VC firm | Stockholm, Sweden | Seed, Series A, Series B, Growth | Biotech, Healthtech, Deep Tech, Climate Tech | Portfolio news, Oct 2026 | 7 Nov 2026 | 3 names, firm email · Unlock | |
| TVM Capital Life Science | VC firm | Munich, Germany | Seed, Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, Sep 2026 | 7 Nov 2026 | 4 names, firm email · Unlock | |
| Overlap Holdings | VC firm | Hicksville, NY | Seed, Series A, Series B | Biotech, AI, Energy, Climate Tech | New fund, Oct 2026 | $16M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| Frazier Life Sciences | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | New fund, Mar 2025 | $7.0B (SEC Form ADV) | 5 Nov 2026 | 6 names · Unlock |
| RA Capital | VC firm | Boston, MA | Pre-seed, Seed, Series A, Series B, Growth, Any stage | Biotech, Healthtech, Climate Tech, Energy | New deal, Aug 2025 | $881M (SEC Form D, 2021) | 4 Nov 2026 | 8 names · Unlock |
| Bramalea Partners | VC firm | Medfield, MA | Series B, Growth | Biotech, Healthtech, AI, Fintech | Portfolio news, Mar 2026 | $78M (SEC Form D, 2021) | 5 Nov 2026 | 2 names · Unlock |
| Gilde Healthcare | Fund manager | Utrecht, Netherlands | Series A, Series B, Growth | Biotech, Healthtech, Medtech, Climate Tech | New fund, Feb 2026 | €3.0B (own site) | 7 Nov 2026 | firm email · Unlock |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Biotech, Healthtech, AI, Robotics | New deal, Sep 2026 | 4 Nov 2026 | 3 names, firm email · Unlock | |
| FCA Venture Management Group | VC firm | Nashville, TN | Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | Portfolio news, May 2026 | $58M (SEC Form ADV) | 5 Nov 2026 | 8 names · Unlock |
| Oxford Science Enterprises | VC firm | Oxford, United Kingdom | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech, AI, Deep Tech | Portfolio news, Mar 2026 | £1.4B (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
You are seeing 25 of 73. The full list adds 48 more investors and 385 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 73 break down
By region
| Region | On this list | Share |
|---|---|---|
| United States | 34 | 47% |
| United Kingdom | 15 | 21% |
| Europe | 24 | 33% |
By US state
| US state | On this list | Share |
|---|---|---|
| California | 11 | 15% |
| New York | 7 | 10% |
| Massachusetts | 3 | 4% |
| Washington | 2 | 3% |
| New Jersey | 2 | 3% |
| Michigan | 2 | 3% |
By European country
| European country | On this list | Share |
|---|---|---|
| France | 6 | 8% |
| Germany | 5 | 7% |
| Sweden | 3 | 4% |
| Belgium | 3 | 4% |
| Netherlands | 2 | 3% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 61 | 84% |
| Fund manager | 4 | 5% |
| Venture debt | 3 | 4% |
| Government or university fund | 2 | 3% |
Method and limits
- Source
- 34 of the 73 rows carry an SEC filing (Form D or Form ADV). All 73 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series B.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 7 Nov 2026.
- Fill rates
- Of 73 rows: stage 73, sector 73, fund size 51, website 73. In the paid file: named decision-makers on 69 rows, firm email on 36, LinkedIn page on 50, check size on 14.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many Series B biotech investors are there?
We list 73 as of November 2026. 39 of the 73 have a fund filing or a dated deal in the last 12 months.
Which Series B biotech investors raised a new fund in the last 12 months?
14 of the 73 have a fund filing dated in the last 12 months. The most recent on this list are Bison Ventures (Oct 2026), Overlap Holdings (Oct 2026) and Cultivation Capital (Sep 2026).
What is the typical fund size of Series B biotech investors?
The median fund size on file for this list is $75M, across the 21 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 52 do not disclose a size there.
How do I contact Series B biotech investors?
The paid file holds 385 named decision-makers across 69 of these 73 and a firm email for 36. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on Series B biotech investors come from?
34 of the 73 rows have an SEC filing on file (Form D or Form ADV) and 39 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Narrower lists
Related lists
Seed biotech investors (300)Series B AI investors (204)Series B SaaS investors (196)Series B healthtech investors (160)Series A biotech investors (153)Pre-seed biotech investors (148)Series B fintech investors (127)Series B deep tech investors (113)Growth-stage biotech investors (109)Series B climate tech investors (98)Series B cybersecurity investors (65)Series B consumer investors (59)Series B medtech investors (57)Series B energy investors (55)Series B B2B investors (46)Series B industrial tech investors (40)Series B mobility investors (39)Series B hardware investors (34)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences and Series B. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.